Université deSherbrooke
Welcome,         Profile    Billing    Logout  
 10 Trials 
11 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Turcotte, Eric
NCT05974579: Safety and Dosimetry of a New Radiotracer to Detect Misfolded SOD1 Associated with Amyotrophic Lateral Sclerosis

Active, not recruiting
1
12
Canada
89Zr-DFO-AP-101
Université de Sherbrooke, Eli Lilly and Company, Chorus Wellness Inc.
Amyotrophic Lateral Sclerosis
12/24
03/25
NCT06147037: A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients with Advanced Solid Tumours

Recruiting
1
110
Canada, US
FPI-2053, [111In]-FPI-2107, [225Ac]-FPI-2068
Fusion Pharmaceuticals Inc., AstraZeneca
Advanced Solid Tumor, Metastatic Colorectal Carcinoma, Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma
12/26
12/27
Turcotte, Éric E
NCT06147037: A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients with Advanced Solid Tumours

Recruiting
1
110
Canada, US
FPI-2053, [111In]-FPI-2107, [225Ac]-FPI-2068
Fusion Pharmaceuticals Inc., AstraZeneca
Advanced Solid Tumor, Metastatic Colorectal Carcinoma, Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma
12/26
12/27
Pavic, Michel
CCTG PR21, NCT04663997: 177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer

Active, not recruiting
2
200
Canada
177Lu-PSMA-617, Docetaxel
Canadian Cancer Trials Group, Prostate Cancer Canada, Novartis Pharmaceuticals
Prostate Cancer
06/25
12/25
KEYNOTE-D78, NCT04879329: A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

Recruiting
2
372
Europe, Canada, Japan, US, RoW
disitamab vedotin, RC48-ADC, pembrolizumab, KEYTRUDA®
Seagen Inc., Merck Sharp & Dohme LLC
Urothelial Carcinoma
11/26
05/28
COBRA, NCT05220098: First-in-Human Study of TAK-280 in Participants With Solid Tumors

Recruiting
1/2
182
Europe, Canada, US, RoW
TAK-280
Takeda, Takeda Development Center Americas, Inc.
Unresectable Locally Advanced or Metastatic Cancer
02/25
07/26
iinnovate-3, NCT05590377 / 2022-002169-14: A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple Myeloma

Completed
1/2
15
Europe, Canada, US, RoW
Modakafusp Alfa, TAK-573, Daratumumab
Takeda, Takeda Development Center Americas, Inc.
Multiple Myeloma
05/24
05/24
NCT06147037: A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients with Advanced Solid Tumours

Recruiting
1
110
Canada, US
FPI-2053, [111In]-FPI-2107, [225Ac]-FPI-2068
Fusion Pharmaceuticals Inc., AstraZeneca
Advanced Solid Tumor, Metastatic Colorectal Carcinoma, Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma
12/26
12/27
NCT06551142: A Study of GSK5764227 in Participants With. Advanced Solid Tumors

Recruiting
1
240
Canada, Japan, US, RoW
GSK5764227, Cisplatin, Carboplatin, Atezolizumab, Pembrolizumab, Durvalumab, Fluorouracil, Folinic acid, Cetuximab, Bevacizumab
GlaxoSmithKline
Neoplasms
07/26
03/27
Guérin, Brigitte
NCT05974579: Safety and Dosimetry of a New Radiotracer to Detect Misfolded SOD1 Associated with Amyotrophic Lateral Sclerosis

Active, not recruiting
1
12
Canada
89Zr-DFO-AP-101
Université de Sherbrooke, Eli Lilly and Company, Chorus Wellness Inc.
Amyotrophic Lateral Sclerosis
12/24
03/25
3TMPO, NCT04000776: (Triple-Tracer Strategy Against Metastatic Prostate Cancer

Completed
N/A
100
Canada
FDG Positron emission tomography (PET) scan, PSMA Positron emission tomography (PET) scan, OCTREOTATE Positron emission tomography (PET) scan, Optional Bone or soft-tissue biopsies
Université de Sherbrooke, Fonds de la Recherche en Santé du Québec, Oncopole, Canadian Cancer Society (CCS), Merck Canada Inc.
Metastatic Castration-resistant Prostate Cancer
03/23
06/23
Turgeon, Guy-Anne
No trials found
Rousseau, Étienne
No trials found

Download Options